Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
Goethals O, Van Ginderen M, Vos A, Cummings MD, Van Der Borght K, Van Wesenbeeck L, Feyaerts M, Verheyen A, Smits V, Van Loock M, Hertogs K, Schols D, Clayton RF. Goethals O, et al. Among authors: hertogs k. Antiviral Res. 2011 Aug;91(2):167-76. doi: 10.1016/j.antiviral.2011.05.011. Epub 2011 Jun 12. Antiviral Res. 2011. PMID: 21669228
Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O, Vos A, Van Ginderen M, Geluykens P, Smits V, Schols D, Hertogs K, Clayton R. Goethals O, et al. Among authors: hertogs k. Virology. 2010 Jul 5;402(2):338-46. doi: 10.1016/j.virol.2010.03.034. Epub 2010 Apr 24. Virology. 2010. PMID: 20421122 Free article.
Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes.
Clayton R, Ohagen A, Nicol F, Del Vecchio AM, Jonckers TH, Goethals O, Van Loock M, Michiels L, Grigsby J, Xu Z, Zhang YP, Gutshall LL, Cunningham M, Jiang H, Bola S, Sarisky RT, Hertogs K. Clayton R, et al. Among authors: hertogs k. Antiviral Res. 2009 Nov;84(2):142-9. doi: 10.1016/j.antiviral.2009.08.003. Epub 2009 Aug 20. Antiviral Res. 2009. PMID: 19699239
The impact of individual human immunodeficiency virus type 1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence.
Van Marck H, Dierynck I, Kraus G, Hallenberger S, Pattery T, Muyldermans G, Geeraert L, Borozdina L, Bonesteel R, Aston C, Shaw E, Chen Q, Martinez C, Koka V, Lee J, Chi E, de Béthune MP, Hertogs K. Van Marck H, et al. Among authors: hertogs k. J Virol. 2009 Sep;83(18):9512-20. doi: 10.1128/JVI.00291-09. Epub 2009 Jul 8. J Virol. 2009. PMID: 19587054 Free PMC article.
96 results